Passage Bio, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- William Chou
- Full Time Employees
- 60
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- One Commerce Square Philadelphia PA United States of America 19103
- IPO Date
- Feb 28, 2020
- CIK
- 0001787297
- Website
- passagebio.com
- Similar Companies
- Business
- Passage Bio, Inc. is a clinical-stage genetic medicines company specializing in the development and advancement of one-time gene therapies targeting neurodegenerative diseases and rare monogenic central nervous system (CNS) disorders. The company develops and offers multiple gene therapy candidates including PBGM01, a functional GLB1 gene therapy encoding β-galactosidase for the treatment of infantile GM1 gangliosidosis; PBFT02, a functional granulin gene encoding progranulin for frontotemporal dementia caused by progranulin deficiency; PBKR03, a functional GALC gene therapy encoding galactosylceramidase for infantile Krabbe disease; PBML04 for metachromatic leukodystrophy; and PBAL05 for amyotrophic lateral sclerosis, with additional programs targeting Huntington’s disease. Passage Bio operates primarily in the United States and maintains a strategic research collaboration and licensing agreement with the University of Pennsylvania's Gene Therapy Program for discovery and preclinical development work. Its manufacturing capabilities are supported through a partnership with Catalent Maryland, Inc., which includes dedicated cGMP manufacturing, packaging, labeling, and distribution services for its gene therapy products. Founded in 2017 and headquartered in Philadelphia, Pennsylvania, Passage Bio is focused on transitioning from preclinical to clinical stages with several programs in clinical development. Recent major company changes include leadership transitions with a new executive team, advancement in clinical trials notably the ongoing multinational Phase 1/2 upliFT-D study evaluating PBFT02 for frontotemporal dementia, and the strategic narrowing of its pediatric lysosomal storage disease pipeline for focused development and potential partnerships. The company has also progressed its manufacturing operations by establishing a dedicated cGMP suite with Catalent to ensure scalable production capacity and supply chain control critical for clinical and future commercial needs. Passage Bio continuously optimizes its pipeline and explores partnerships to accelerate the development and accessibility of its gene therapy candidates for rare CNS diseases.
Passage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updates
Analysts Set Passage Bio, Inc. (NASDAQ:PASG) PT at $42.67
Passage Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Recent Business Highlights
Passage Bio to Participate in Upcoming Investor Conferences
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Price Target at $42.67
Analyzing Passage Bio (NASDAQ:PASG) and Vir Biotechnology (NASDAQ:VIR)
Financial Comparison: Passage Bio (NASDAQ:PASG) versus PepGen (NASDAQ:PEPG)
Brokerages Set Passage Bio, Inc. (NASDAQ:PASG) Target Price at $42.67
Passage Bio Reports Third Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio to Present at Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Passage Bio to Participate in Chardan's 9th Annual Genetic Medicines Conference
Wall Street Analysts Think Passage Bio (PASG) Could Surge 731%: Read This Before Placing a Bet
Passage Bio to Participate in H.C. Wainwright 27th Annual Global Investment Conference
Wall Street Analysts Believe Passage Bio (PASG) Could Rally 1415.15%: Here's is How to Trade
Passage Bio Reports Second Quarter 2025 Financial Results and Provides Recent Business Highlights
Passage Bio Announces 1-for-20 Reverse Stock Split
Passage Bio Reports Updated Interim Data from upliFT-D Study and Provides Program Update
Squarepoint Ops LLC Has $36,000 Stake in Passage Bio, Inc. (NASDAQ:PASG)
Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights